159 related articles for article (PubMed ID: 15885456)
1. Factors affecting the characteristics of rapidly disintegrating tablets in the mouth prepared by the crystalline transition of amorphous sucrose.
Sugimoto M; Maejima T; Narisawa S; Matsubara K; Yoshino H
Int J Pharm; 2005 May; 296(1-2):64-72. PubMed ID: 15885456
[TBL] [Abstract][Full Text] [Related]
2. Development of manufacturing method for rapidly disintegrating oral tablets using the crystalline transition of amorphous sucrose.
Sugimoto M; Narisawa S; Matsubara K; Yoshino H; Nakano M; Handa T
Int J Pharm; 2006 Aug; 320(1-2):71-8. PubMed ID: 16750604
[TBL] [Abstract][Full Text] [Related]
3. The preparation of rapidly disintegrating tablets in the mouth.
Sugimoto M; Matsubara K; Koida Y; Kobayashi M
Pharm Dev Technol; 2001 Nov; 6(4):487-93. PubMed ID: 11775950
[TBL] [Abstract][Full Text] [Related]
4. Effect of formulated ingredients on rapidly disintegrating oral tablets prepared by the crystalline transition method.
Sugimoto M; Narisawa S; Matsubara K; Yoshino H; Nakano M; Handa T
Chem Pharm Bull (Tokyo); 2006 Feb; 54(2):175-80. PubMed ID: 16462059
[TBL] [Abstract][Full Text] [Related]
5. Particle size distribution and evolution in tablet structure during and after compaction.
Fichtner F; Rasmuson A; Alderborn G
Int J Pharm; 2005 Mar; 292(1-2):211-25. PubMed ID: 15725568
[TBL] [Abstract][Full Text] [Related]
6. Water-solid interactions. III. Effect of glass transition temperature, Tg, and processing on tensile strength of compacts of lactose and lactose/polyvinyl pyrrolidone.
Stubberud L; Arwidsson HG; Hjortsberg V; Graffner C
Pharm Dev Technol; 1996 Jul; 1(2):195-204. PubMed ID: 9552346
[TBL] [Abstract][Full Text] [Related]
7. Amorphous Formulation and in Vitro Performance Testing of Instantly Disintegrating Buccal Tablets for the Emergency Delivery of Naloxone.
Alqurshi A; Kumar Z; McDonald R; Strang J; Buanz A; Ahmed S; Allen E; Cameron P; Rickard JA; Sandhu V; Holt C; Stansfield R; Taylor D; Forbes B; Royall PG
Mol Pharm; 2016 May; 13(5):1688-98. PubMed ID: 26977787
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a novel sugar coating method for moisture protective tablets.
Ando M; Ito R; Ozeki Y; Nakayama Y; Nabeshima T
Int J Pharm; 2007 May; 336(2):319-28. PubMed ID: 17258875
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols.
Kuno Y; Kojima M; Ando S; Nakagami H
J Control Release; 2005 Jun; 105(1-2):16-22. PubMed ID: 15955365
[TBL] [Abstract][Full Text] [Related]
10. Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity.
Bi Y; Sunada H; Yonezawa Y; Danjo K; Otsuka A; Iida K
Chem Pharm Bull (Tokyo); 1996 Nov; 44(11):2121-7. PubMed ID: 8945778
[TBL] [Abstract][Full Text] [Related]
11. Investigating the moisture sorption behavior of amorphous sucrose using a dynamic humidity generating instrument.
Yu X; Kappes SM; Bello-Perez LA; Schmidt SJ
J Food Sci; 2008 Jan; 73(1):E25-35. PubMed ID: 18211350
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of rapidly disintegrating tablets prepared by a direct compression method.
Bi YX; Sunada H; Yonezawa Y; Danjo K
Drug Dev Ind Pharm; 1999 May; 25(5):571-81. PubMed ID: 10219525
[TBL] [Abstract][Full Text] [Related]
13. Drug release control and system understanding of sucrose esters matrix tablets by artificial neural networks.
Chansanroj K; Petrović J; Ibrić S; Betz G
Eur J Pharm Sci; 2011 Oct; 44(3):321-31. PubMed ID: 21878388
[TBL] [Abstract][Full Text] [Related]
14. Quantification of low levels of amorphous content in sucrose by hyperDSC.
Lappalainen M; Pitkänen I; Harjunen P
Int J Pharm; 2006 Jan; 307(2):150-5. PubMed ID: 16288841
[TBL] [Abstract][Full Text] [Related]
15. Relationships between the effective interparticulate contact area and the tensile strength of tablets of amorphous and crystalline lactose of varying particle size.
Sebhatu T; Alderborn G
Eur J Pharm Sci; 1999 Aug; 8(4):235-42. PubMed ID: 10425373
[TBL] [Abstract][Full Text] [Related]
16. Effect of polymer, plasticizer and filler on orally disintegrating film.
Liew KB; Tan YT; Peh KK
Drug Dev Ind Pharm; 2014 Jan; 40(1):110-9. PubMed ID: 23311593
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of co-processed excipients used for direct compression of orally disintegrating tablets (ODT) using novel disintegration apparatus.
Brniak W; Jachowicz R; Krupa A; Skorka T; Niwinski K
Pharm Dev Technol; 2013; 18(2):464-74. PubMed ID: 22881600
[TBL] [Abstract][Full Text] [Related]
18. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
[TBL] [Abstract][Full Text] [Related]
19. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
Dhumal RS; Shimpi SL; Paradkar AR
Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
[TBL] [Abstract][Full Text] [Related]
20. Preparation and evaluation of orally rapidly disintegrating tablets containing taste-masked particles using one-step dry-coated tablets technology.
Kondo K; Niwa T; Ozeki Y; Ando M; Danjo K
Chem Pharm Bull (Tokyo); 2011; 59(10):1214-20. PubMed ID: 21963629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
